losmapimod
Jump to navigation
Jump to search
Contraindications
Mechanism of action
- inhibits p38MAPKs
- reduces serum C-reactive protein & serum pro-BNP at 4 weeks after myocardial infarction,
- does not reduce a composite outcome of cardiovascular death, MI, or recurrent ischemia evascularization at 12 weeks relative to placebo (8.1% vs 7.0%)
More general terms
Additional terms
References
- ↑ O'Donoghue ML et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial. JAMA 2016 Apr 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27043082